Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides
Overview
Affiliations
A monoclonal antibody (B-5G10) was produced which specifically recognizes the Mr 150,000/130,000 VLA-4 complex on the surface of human cells. Cross-linking studies indicated that the Mr 150,000 alpha 4 subunit of VLA-4 is in noncovalent 1:1 association with the Mr 130,000 VLA beta subunit. In the absence of cross-linking, the VLA-4 alpha 4 beta subunit complex was easily dissociated, especially in Nonidet P-40 detergent, or at elevated pH (above 8.0). Studies of dissociated subunits showed that B-5G10 recognizes an epitope on the Mr 150,000 alpha 4 subunit of VLA-4, whereas the beta subunit is immunologically identical to the Mr 130,000 beta subunit common to all VLA heterodimers. VLA-4 is widely distributed on hematopoietic cells, including thymocytes, peripheral blood lymphocytes, monocytes, activated T cells, T and B lymphoblastoid cell lines, and myeloid cell lines. However, VLA-4 is only weakly expressed on most adherent cell lines tested. Immunoprecipitates of VLA-4 often contain additional proteins of Mr 80,000 and Mr 70,000. These are probably derived from the Mr 150,000 alpha 4 subunit because: 1) they are both recognized by anti-alpha 4 sera, but not anti-beta sera; 2) the sum of their sizes is equal to the size of alpha 4; 3) they are selectively coexpressed with alpha 4 and not other VLA alpha subunits; 4) the Mr 80,000 protein has an identical NH2-terminal sequence to alpha 4; 5) like alpha 4, the Mr 70,000 and 80,000 peptides can variably associate with the VLA beta subunit; and 6) trypsin appears to cleave the Mr 150,000 alpha 4 subunit into products of Mr 70,000 and 80,000.
Tang H, Bie C, Guo L, Zhong L, Tang S Exp Ther Med. 2023; 25(6):298.
PMID: 37229320 PMC: 10203751. DOI: 10.3892/etm.2023.11997.
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J, Keyashian K, Rubin S, Wang J, Buckman C, Sinha S Clin Exp Gastroenterol. 2021; 14:333-342.
PMID: 34466013 PMC: 8402953. DOI: 10.2147/CEG.S293272.
Park J, Jiang Y, Zhou J, Gong H, Mohapatra A, Heo J Sci Adv. 2021; 7(25).
PMID: 34134990 PMC: 8208717. DOI: 10.1126/sciadv.abf7820.
Location First: Targeting Acute Myeloid Leukemia Within Its Niche.
Pievani A, Biondi M, Tomasoni C, Biondi A, Serafini M J Clin Med. 2020; 9(5).
PMID: 32443460 PMC: 7290711. DOI: 10.3390/jcm9051513.
Bergerhausen L, Grosche J, Meissner J, Hecker C, Caliandro M, Westerhausen C Antioxidants (Basel). 2020; 9(3).
PMID: 32164274 PMC: 7139957. DOI: 10.3390/antiox9030227.